{"filing":{"accession_number":"0001178670-26-000060","cik":"0001178670","ticker":"ALNY","company_name":"ALNYLAM PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"alny-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm"},"events":[{"id":22123,"run_id":19992,"accession_number":"0001178670-26-000060","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Alnylam's Q2 2026 financial results, including total revenues of $1,290.9 million (67% growth), net product revenues of $1,172.1 million (74% growth), and GAAP net income of $164.5 million. The filing explicitly states \"Alnylam Pharmaceuticals, Inc. (the 'Company') announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The results are material to investors, showing significant revenue growth driven by AMVUTTRA and revised full-year TTR guidance.","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21974,"accession_number":"0001178670-26-000060","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Alnylam's Q2 2026 financial results, including total revenues of $1,290.9 million (67% growth), net product revenues of $1,172.1 million (74% growth), and GAAP net income of $164.5 million. The filing explicitly states \"Alnylam Pharmaceuticals, Inc. (the 'Company') announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The results are material to investors, showing significant revenue growth driven by AMVUTTRA and revised full-year TTR guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:07:49.366439+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21974,"accession_number":"0001178670-26-000060","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Alnylam's Q2 2026 financial results, including total revenues of $1,290.9 million (67% growth), net product revenues of $1,172.1 million (74% growth), and GAAP net income of $164.5 million. The filing explicitly states \"Alnylam Pharmaceuticals, Inc. (the 'Company') announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The results are material to investors, showing significant revenue growth driven by AMVUTTRA and revised full-year TTR guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:07:49.366439+00:00","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-07-30"}]}